Data presented from a Phase I/II trial presented at #ESMO25 shows the first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated antitumor activity.
Learn more about the trial, led by our Dr. Timothy Yap: spr.ly/63322A4lni #OncSky #EndCancer
Learn more about the trial, led by our Dr. Timothy Yap: spr.ly/63322A4lni #OncSky #EndCancer
ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma
The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor activity, particularly in patients with refractory mesothelioma, according to results from a trial led by researchers from The University of Texas MD Anderson Cancer Center.
spr.ly
October 19, 2025 at 5:19 PM
Data presented from a Phase I/II trial presented at #ESMO25 shows the first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated antitumor activity.
Learn more about the trial, led by our Dr. Timothy Yap: spr.ly/63322A4lni #OncSky #EndCancer
Learn more about the trial, led by our Dr. Timothy Yap: spr.ly/63322A4lni #OncSky #EndCancer
Data from a Phase II clinical trial published today in @nejm.org and presented at #ESMO25 shows belzutifan shrank tumors in patients with hard-to-treat neuroendocrine tumors and improved symptoms without surgery.
Learn more: spr.ly/63321ANmPU #EndCancer
Learn more: spr.ly/63321ANmPU #EndCancer
ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients
Pheochromocytoma and paraganglioma (PPGL) are rare, hard-to-treat neuroendocrine tumors that form in the adrenal glands or in the extra-adrenal paraganglia Study found belzutifan shrank tumors and improved symptoms without surgery Belzutifan is the first oral and only FDA-approved treatment for patients with advanced, inoperable, or metastatic PPGL FDA granted approval
spr.ly
October 18, 2025 at 5:00 PM
Data from a Phase II clinical trial published today in @nejm.org and presented at #ESMO25 shows belzutifan shrank tumors in patients with hard-to-treat neuroendocrine tumors and improved symptoms without surgery.
Learn more: spr.ly/63321ANmPU #EndCancer
Learn more: spr.ly/63321ANmPU #EndCancer
Results from a trial found a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma whose disease progressed following immunotherapy.
Learn more about the data presented at #ESMO25: www.mdanderson.org/newsroom/res... #EndCancer
Learn more about the data presented at #ESMO25: www.mdanderson.org/newsroom/res... #EndCancer
ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients
Study found patients treated with combination of lenvatinib and everolimus lived longer without disease progression First head-to-head study comparing second-line treatments lenvatinib plus everolimus vs.
www.mdanderson.org
October 18, 2025 at 12:04 PM
Results from a trial found a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma whose disease progressed following immunotherapy.
Learn more about the data presented at #ESMO25: www.mdanderson.org/newsroom/res... #EndCancer
Learn more about the data presented at #ESMO25: www.mdanderson.org/newsroom/res... #EndCancer
Results from a Phase I/II SOHO-01 clinical trial found over 70% of non-small cell lung cancer patients studied saw tumors shrink or disappear after taking sevabertinib, a targeted therapy drug.
More about these results presented at #ESMO25: spr.ly/6048A2aYs
More about these results presented at #ESMO25: spr.ly/6048A2aYs
ESMO 2025: Oral drug demonstrates promising anti-tumor activity in patients with advanced lung cancer
The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by researchers at The University of Texas MD Anderson Cancer Center.
spr.ly
October 17, 2025 at 8:00 PM
Results from a Phase I/II SOHO-01 clinical trial found over 70% of non-small cell lung cancer patients studied saw tumors shrink or disappear after taking sevabertinib, a targeted therapy drug.
More about these results presented at #ESMO25: spr.ly/6048A2aYs
More about these results presented at #ESMO25: spr.ly/6048A2aYs
From leveraging molecular profiling to understand rare cancers to a first-in-class treatment for refractory mesothelioma, presentations from MD Anderson researchers at #ESMO25 will showcase our application of advanced precision oncology: spr.ly/6016ALNNC @myesmo.bsky.social #EndCancer
5 notable presentations from ESMO 2025
At the 2025 European Society for Medical Oncology (ESMO) Congress, MD Anderson researchers will present many significant studies that showcase our application of advanced precision oncology. Highlights include molecular profiling of rare cancers, new treatments for HER2 positive colorectal cancer, mesothelioma and rare neuroendocrine tumors, and second-line therapy outcomes in chronic myeloid leukemia.
spr.ly
October 15, 2025 at 10:00 PM
From leveraging molecular profiling to understand rare cancers to a first-in-class treatment for refractory mesothelioma, presentations from MD Anderson researchers at #ESMO25 will showcase our application of advanced precision oncology: spr.ly/6016ALNNC @myesmo.bsky.social #EndCancer
Our @oncoalert.bsky.social 🚨Faculty Biagio Ricciuti 🇺🇸with his TOP picks of #LungCancer 🫁 WATCH HERE 👉 www.youtube.com/watch?v=eRIS...
#ESMO25
#ESMO25
TOP3 Hightlights in #LungCancer from #ESMO25
YouTube video by OncoAlert 360
www.youtube.com
November 18, 2025 at 4:36 PM
Our @oncoalert.bsky.social 🚨Faculty Biagio Ricciuti 🇺🇸with his TOP picks of #LungCancer 🫁 WATCH HERE 👉 www.youtube.com/watch?v=eRIS...
#ESMO25
#ESMO25
Dear Colleagues in #ESMO25
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨will be Live from Lisbon covering this Great meeting
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨will be Live from Lisbon covering this Great meeting
November 7, 2025 at 1:47 PM
Dear Colleagues in #ESMO25
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨will be Live from Lisbon covering this Great meeting
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨will be Live from Lisbon covering this Great meeting
THE #ESMO25 COMPLETE Newsletter by OncoAlert 🚨MONDAY Nov 3rd is the FINAL DAY TO GET IT‼️ TO GET IT REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
5⃣0⃣of our pick of TOP Trials Presented in Berlin🇩🇪
5⃣0⃣of our pick of TOP Trials Presented in Berlin🇩🇪
October 31, 2025 at 2:43 PM
THE #ESMO25 COMPLETE Newsletter by OncoAlert 🚨MONDAY Nov 3rd is the FINAL DAY TO GET IT‼️ TO GET IT REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
5⃣0⃣of our pick of TOP Trials Presented in Berlin🇩🇪
5⃣0⃣of our pick of TOP Trials Presented in Berlin🇩🇪
Our #OncoAlertAF 🚨Colleague Nicholas Hornstein 🇺🇸 of @NorthwellHealth with TOP picks of #GIOncology Presented at #ESMO25 🇩🇪 👉 youtu.be/tVaVJ7pg50I
for the OncoAlert TOP3 Series post ESMO 2025, more to come..
✅NICHE2
✅STELLAR 303
for the OncoAlert TOP3 Series post ESMO 2025, more to come..
✅NICHE2
✅STELLAR 303
TOP 3 Highlights in GI Oncology for #ESMO25 by Dr. Nicholas Hornstein
Our OncoAlert Faculty Dr. Nicholas Hornstein from the Northwell Health shares his Top GI Oncology picks from ESMO 2025 in Berlin, breaking down the most impactful GI trials shaping the field…
youtu.be
October 31, 2025 at 2:32 PM
Our #OncoAlertAF 🚨Colleague Nicholas Hornstein 🇺🇸 of @NorthwellHealth with TOP picks of #GIOncology Presented at #ESMO25 🇩🇪 👉 youtu.be/tVaVJ7pg50I
for the OncoAlert TOP3 Series post ESMO 2025, more to come..
✅NICHE2
✅STELLAR 303
for the OncoAlert TOP3 Series post ESMO 2025, more to come..
✅NICHE2
✅STELLAR 303
Our OncoAlert 🚨Faculty @weoncologists.bsky.social 🇺🇸with his TOP picks of #ProstateCancer Trials. WATCH HERE 👉 youtu.be/u1ehzE_lFtY
Trials were Presented at #ESMO25 🇩🇪 and we have included them as part of our OncoAlert TOP3 Series post ESMO 2025, more to come..
✅EMBARK
✅CAPItello-281
✅PETRANHA
Trials were Presented at #ESMO25 🇩🇪 and we have included them as part of our OncoAlert TOP3 Series post ESMO 2025, more to come..
✅EMBARK
✅CAPItello-281
✅PETRANHA
TOP3 Highlights for #ProstateCancer from #ESMO25 by Dr. Gil Morgan
YouTube video by OncoAlert 360
youtu.be
October 30, 2025 at 12:38 PM
Our OncoAlert 🚨Faculty @weoncologists.bsky.social 🇺🇸with his TOP picks of #ProstateCancer Trials. WATCH HERE 👉 youtu.be/u1ehzE_lFtY
Trials were Presented at #ESMO25 🇩🇪 and we have included them as part of our OncoAlert TOP3 Series post ESMO 2025, more to come..
✅EMBARK
✅CAPItello-281
✅PETRANHA
Trials were Presented at #ESMO25 🇩🇪 and we have included them as part of our OncoAlert TOP3 Series post ESMO 2025, more to come..
✅EMBARK
✅CAPItello-281
✅PETRANHA
Our Collaborators at @high5md have gathered top international experts in Lung Cancer
WATCH HERE: buff.ly/3NuVFAr
They have uploaded their full reports from ESMO25 and available on demand. Visit them for the Top News out of Berlin!
WATCH HERE: buff.ly/3NuVFAr
They have uploaded their full reports from ESMO25 and available on demand. Visit them for the Top News out of Berlin!
October 24, 2025 at 1:43 PM
Our Collaborators at @high5md have gathered top international experts in Lung Cancer
WATCH HERE: buff.ly/3NuVFAr
They have uploaded their full reports from ESMO25 and available on demand. Visit them for the Top News out of Berlin!
WATCH HERE: buff.ly/3NuVFAr
They have uploaded their full reports from ESMO25 and available on demand. Visit them for the Top News out of Berlin!
Dear Colleagues, Our Collaborators at COR2ED Invite you to watch Highlights from #ESMO25
WATCH HERE 👉 cor2ed.com/esmo-2025/br...
Straight from Berlin, Experts share their views on new data on #BreastCancer & #GynOnc
NOW ON DEMAND
WATCH HERE 👉 cor2ed.com/esmo-2025/br...
Straight from Berlin, Experts share their views on new data on #BreastCancer & #GynOnc
NOW ON DEMAND
October 23, 2025 at 10:02 AM
Dear Colleagues, Our Collaborators at COR2ED Invite you to watch Highlights from #ESMO25
WATCH HERE 👉 cor2ed.com/esmo-2025/br...
Straight from Berlin, Experts share their views on new data on #BreastCancer & #GynOnc
NOW ON DEMAND
WATCH HERE 👉 cor2ed.com/esmo-2025/br...
Straight from Berlin, Experts share their views on new data on #BreastCancer & #GynOnc
NOW ON DEMAND
Colleagues, the Complete #ESMO25 OncoAlert Newsletter is coming Oct 27‼️ GET IT HERE👉 oncoalert.m-pages.com/nhMpwe/oncoa...
50 of our PICKS of TOP Trials out of Berlin 🇩🇪
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social
50 of our PICKS of TOP Trials out of Berlin 🇩🇪
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social
October 22, 2025 at 2:25 PM
Colleagues, the Complete #ESMO25 OncoAlert Newsletter is coming Oct 27‼️ GET IT HERE👉 oncoalert.m-pages.com/nhMpwe/oncoa...
50 of our PICKS of TOP Trials out of Berlin 🇩🇪
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social
50 of our PICKS of TOP Trials out of Berlin 🇩🇪
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social
Colleagues at #ESMO25
Dr Herbert Loong shares his perspectives on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at ESMO 2025. Go to the COR2ED website to watch his video update and download the accompanying slides
cor2ed.com/esmo-2025/on...
Dr Herbert Loong shares his perspectives on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at ESMO 2025. Go to the COR2ED website to watch his video update and download the accompanying slides
cor2ed.com/esmo-2025/on...
October 20, 2025 at 9:30 AM
Colleagues at #ESMO25
Dr Herbert Loong shares his perspectives on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at ESMO 2025. Go to the COR2ED website to watch his video update and download the accompanying slides
cor2ed.com/esmo-2025/on...
Dr Herbert Loong shares his perspectives on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at ESMO 2025. Go to the COR2ED website to watch his video update and download the accompanying slides
cor2ed.com/esmo-2025/on...
Dear COLLEAGUES, DAY THREE 3️⃣OF OncoAlert Newsletter #ESMO25 🇩🇪COMES OUT TOMORROW MORNING 6:30 AM REGISTER HERE👉 buff.ly/h9UN37G
✅ HARMONi-6 (Lancet)
✅OptiTROP-Lung04 (NEJM)
✅PSMAddition
✅CAPItello (Annals of Oncology)
✅Enza Rad
✅Disitamab vedotin + toripalimab
✅ASCENT-03 (NEJM)
✅Destiny breast 09
✅ HARMONi-6 (Lancet)
✅OptiTROP-Lung04 (NEJM)
✅PSMAddition
✅CAPItello (Annals of Oncology)
✅Enza Rad
✅Disitamab vedotin + toripalimab
✅ASCENT-03 (NEJM)
✅Destiny breast 09
October 19, 2025 at 3:49 PM
Dear COLLEAGUES, DAY THREE 3️⃣OF OncoAlert Newsletter #ESMO25 🇩🇪COMES OUT TOMORROW MORNING 6:30 AM REGISTER HERE👉 buff.ly/h9UN37G
✅ HARMONi-6 (Lancet)
✅OptiTROP-Lung04 (NEJM)
✅PSMAddition
✅CAPItello (Annals of Oncology)
✅Enza Rad
✅Disitamab vedotin + toripalimab
✅ASCENT-03 (NEJM)
✅Destiny breast 09
✅ HARMONi-6 (Lancet)
✅OptiTROP-Lung04 (NEJM)
✅PSMAddition
✅CAPItello (Annals of Oncology)
✅Enza Rad
✅Disitamab vedotin + toripalimab
✅ASCENT-03 (NEJM)
✅Destiny breast 09
Our Collaborators at @high5md have gathered top international experts in #BreastCancer and commence their full reports from #ESMO25 starting TODAY Sunday October 19 at 6pm CET. Follow for the Top News out of Berlin!
high5oncology.tv/meeting-cove...
high5oncology.tv/meeting-cove...
October 19, 2025 at 11:03 AM
Our Collaborators at @high5md have gathered top international experts in #BreastCancer and commence their full reports from #ESMO25 starting TODAY Sunday October 19 at 6pm CET. Follow for the Top News out of Berlin!
high5oncology.tv/meeting-cove...
high5oncology.tv/meeting-cove...
Colleagues at #ESMO25 , Join our Collaborators at COR2ED and Dr. Lizzy Smyth straight from Berlin 👉 cor2ed.com/esmo-2025/up...
Dr Smyth will review key studies including MATTERHORN, LEAP-014, and SKYSCRAPER-07 — and discuss whether these results could change clinical practice.
Dr Smyth will review key studies including MATTERHORN, LEAP-014, and SKYSCRAPER-07 — and discuss whether these results could change clinical practice.
October 19, 2025 at 9:00 AM
Colleagues at #ESMO25 , Join our Collaborators at COR2ED and Dr. Lizzy Smyth straight from Berlin 👉 cor2ed.com/esmo-2025/up...
Dr Smyth will review key studies including MATTERHORN, LEAP-014, and SKYSCRAPER-07 — and discuss whether these results could change clinical practice.
Dr Smyth will review key studies including MATTERHORN, LEAP-014, and SKYSCRAPER-07 — and discuss whether these results could change clinical practice.
Colleagues at #ESMO25 Big News from #APCCC26 🚨APCCC is opening a Call for Abstracts!
❓ SUBMIT YOUR QUESTION👉 apccc.org/apccc-questi...
⭐ Full details & submission 👉 apccc.org
Creating new opportunities for younger investigators & the next generation of leaders in advanced #ProstateCancer
❓ SUBMIT YOUR QUESTION👉 apccc.org/apccc-questi...
⭐ Full details & submission 👉 apccc.org
Creating new opportunities for younger investigators & the next generation of leaders in advanced #ProstateCancer
APCCC Question Submission - APCCC
apccc.org
October 19, 2025 at 8:19 AM
Colleagues at #ESMO25 Big News from #APCCC26 🚨APCCC is opening a Call for Abstracts!
❓ SUBMIT YOUR QUESTION👉 apccc.org/apccc-questi...
⭐ Full details & submission 👉 apccc.org
Creating new opportunities for younger investigators & the next generation of leaders in advanced #ProstateCancer
❓ SUBMIT YOUR QUESTION👉 apccc.org/apccc-questi...
⭐ Full details & submission 👉 apccc.org
Creating new opportunities for younger investigators & the next generation of leaders in advanced #ProstateCancer
Dear Colleagues at #ESMO25
Join VJOncology at booth (P.2013) during ESMO 2025! Submit your questions for top Oncology experts—selected queries will be answered live on camera and shared across VJOncology’s platforms.
SUBMIT Your Questions HERE:
bit.ly/46Ook0u
Join VJOncology at booth (P.2013) during ESMO 2025! Submit your questions for top Oncology experts—selected queries will be answered live on camera and shared across VJOncology’s platforms.
SUBMIT Your Questions HERE:
bit.ly/46Ook0u
October 19, 2025 at 8:00 AM
Dear Colleagues at #ESMO25
Join VJOncology at booth (P.2013) during ESMO 2025! Submit your questions for top Oncology experts—selected queries will be answered live on camera and shared across VJOncology’s platforms.
SUBMIT Your Questions HERE:
bit.ly/46Ook0u
Join VJOncology at booth (P.2013) during ESMO 2025! Submit your questions for top Oncology experts—selected queries will be answered live on camera and shared across VJOncology’s platforms.
SUBMIT Your Questions HERE:
bit.ly/46Ook0u
The OncoAlert🚨Round Up Day 2 of #ESMO25
Watch Here👉 youtu.be/gJQU0EojIME & REGISTER at ww.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
OUR TOP 5⃣ PICKS Presented Oct 18, 2025
⭐️DESTINY Breast 11 (291O)
⭐️DESTINY Breast 5 (LBA 1)
⭐️evERA (LBA 16)
⭐️RAMPART ( LBA93 )
⭐️KEYNOTE-905 ( LBA2 )
Watch Here👉 youtu.be/gJQU0EojIME & REGISTER at ww.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
OUR TOP 5⃣ PICKS Presented Oct 18, 2025
⭐️DESTINY Breast 11 (291O)
⭐️DESTINY Breast 5 (LBA 1)
⭐️evERA (LBA 16)
⭐️RAMPART ( LBA93 )
⭐️KEYNOTE-905 ( LBA2 )
The OncoAlert TOP5 of Day 2 of #esmo25 :DESTINY Breast 11, DESTINY Breast 05, KN905, evERA & RAMPART
🚨 Welcome to OncoAlert’s Top 5 Picks from ESMO 2025! 🚨
We’re breaking down the most practice-changing data from Day 2 of the ESMO Congress — covering breast, bladder, and renal cancers. From the…
youtu.be
October 19, 2025 at 5:29 AM
The OncoAlert🚨Round Up Day 2 of #ESMO25
Watch Here👉 youtu.be/gJQU0EojIME & REGISTER at ww.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
OUR TOP 5⃣ PICKS Presented Oct 18, 2025
⭐️DESTINY Breast 11 (291O)
⭐️DESTINY Breast 5 (LBA 1)
⭐️evERA (LBA 16)
⭐️RAMPART ( LBA93 )
⭐️KEYNOTE-905 ( LBA2 )
Watch Here👉 youtu.be/gJQU0EojIME & REGISTER at ww.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
OUR TOP 5⃣ PICKS Presented Oct 18, 2025
⭐️DESTINY Breast 11 (291O)
⭐️DESTINY Breast 5 (LBA 1)
⭐️evERA (LBA 16)
⭐️RAMPART ( LBA93 )
⭐️KEYNOTE-905 ( LBA2 )
Dear COLLEAGUES, DAY TWO2️⃣ OF OncoAlert Newsletter #ESMO25 🇩🇪 COMES OUT TOMORROW MORNING 6:30 AM REGISTER HERE👉 buff.ly/RkOToac
COVERING:
✅ DESTINY BReast11
✅Viktoria-1
✅evERA
✅RAMPART
✅NESCIO
✅OPTIC
✅ENGOT-ov65/KEYNOTE-B96
✅KEYNOTE-905
✅MDT BRidge
& Much More
COVERING:
✅ DESTINY BReast11
✅Viktoria-1
✅evERA
✅RAMPART
✅NESCIO
✅OPTIC
✅ENGOT-ov65/KEYNOTE-B96
✅KEYNOTE-905
✅MDT BRidge
& Much More
October 18, 2025 at 3:43 PM
Dear COLLEAGUES, DAY TWO2️⃣ OF OncoAlert Newsletter #ESMO25 🇩🇪 COMES OUT TOMORROW MORNING 6:30 AM REGISTER HERE👉 buff.ly/RkOToac
COVERING:
✅ DESTINY BReast11
✅Viktoria-1
✅evERA
✅RAMPART
✅NESCIO
✅OPTIC
✅ENGOT-ov65/KEYNOTE-B96
✅KEYNOTE-905
✅MDT BRidge
& Much More
COVERING:
✅ DESTINY BReast11
✅Viktoria-1
✅evERA
✅RAMPART
✅NESCIO
✅OPTIC
✅ENGOT-ov65/KEYNOTE-B96
✅KEYNOTE-905
✅MDT BRidge
& Much More
Dear Colleagues at #ESMO25
A Great pleasure to Introduce our Faculty Dr. Petros Grivas 🇺🇸 from Fred Hutch who talks to us about all of the Exciting #BladderCancer Science being Presented in Berlin
✅ Keynote 905
✅ Disitamab vedotin (DV) plus toripalimab
✅ IMvigor011
And much more
A Great pleasure to Introduce our Faculty Dr. Petros Grivas 🇺🇸 from Fred Hutch who talks to us about all of the Exciting #BladderCancer Science being Presented in Berlin
✅ Keynote 905
✅ Disitamab vedotin (DV) plus toripalimab
✅ IMvigor011
And much more
October 18, 2025 at 1:48 PM
Dear Colleagues at #ESMO25
A Great pleasure to Introduce our Faculty Dr. Petros Grivas 🇺🇸 from Fred Hutch who talks to us about all of the Exciting #BladderCancer Science being Presented in Berlin
✅ Keynote 905
✅ Disitamab vedotin (DV) plus toripalimab
✅ IMvigor011
And much more
A Great pleasure to Introduce our Faculty Dr. Petros Grivas 🇺🇸 from Fred Hutch who talks to us about all of the Exciting #BladderCancer Science being Presented in Berlin
✅ Keynote 905
✅ Disitamab vedotin (DV) plus toripalimab
✅ IMvigor011
And much more
Our Collaborators at high5Oncology have gathered top international experts in Lung Cancer and commence their full reports from ESMO25 starting Sunday October 19 at 6pm CET. Follow for the Top News out of Berlin!
high5oncology.tv/meeting-cove...
high5oncology.tv/meeting-cove...
October 18, 2025 at 1:30 PM
Our Collaborators at high5Oncology have gathered top international experts in Lung Cancer and commence their full reports from ESMO25 starting Sunday October 19 at 6pm CET. Follow for the Top News out of Berlin!
high5oncology.tv/meeting-cove...
high5oncology.tv/meeting-cove...
Dear Colleaguest at #ESMO25
A warm invite to our Flagship Event: REGISTER👉 oncoalert.m-pages.com/rnaYzs/the-5...
OncoAlert, ESGO, ESSO, MASCC, SIOG & our esteemed faculty invite you to the 2026 #OncoAlertColloquium this coming february
A warm invite to our Flagship Event: REGISTER👉 oncoalert.m-pages.com/rnaYzs/the-5...
OncoAlert, ESGO, ESSO, MASCC, SIOG & our esteemed faculty invite you to the 2026 #OncoAlertColloquium this coming february
October 18, 2025 at 12:47 PM
Dear Colleaguest at #ESMO25
A warm invite to our Flagship Event: REGISTER👉 oncoalert.m-pages.com/rnaYzs/the-5...
OncoAlert, ESGO, ESSO, MASCC, SIOG & our esteemed faculty invite you to the 2026 #OncoAlertColloquium this coming february
A warm invite to our Flagship Event: REGISTER👉 oncoalert.m-pages.com/rnaYzs/the-5...
OncoAlert, ESGO, ESSO, MASCC, SIOG & our esteemed faculty invite you to the 2026 #OncoAlertColloquium this coming february
Oncology experts will be joining our friends and collaborators at COR2ED in Berlin for #ESMO25
Coming Soon👉 cor2ed.com/esmo-2025/up...
They will share their insights on the latest data on #BladderCancer #KidneyCancer #ProstateCancer #LungCancer #BreastCancer #GynOnc and Upper GI Cancers
Sign up
Coming Soon👉 cor2ed.com/esmo-2025/up...
They will share their insights on the latest data on #BladderCancer #KidneyCancer #ProstateCancer #LungCancer #BreastCancer #GynOnc and Upper GI Cancers
Sign up
October 18, 2025 at 12:30 PM
Oncology experts will be joining our friends and collaborators at COR2ED in Berlin for #ESMO25
Coming Soon👉 cor2ed.com/esmo-2025/up...
They will share their insights on the latest data on #BladderCancer #KidneyCancer #ProstateCancer #LungCancer #BreastCancer #GynOnc and Upper GI Cancers
Sign up
Coming Soon👉 cor2ed.com/esmo-2025/up...
They will share their insights on the latest data on #BladderCancer #KidneyCancer #ProstateCancer #LungCancer #BreastCancer #GynOnc and Upper GI Cancers
Sign up